Infectious disease comorbidities adversely affecting substance users with HIV: Hepatitis C and tuberculosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 1, 2010, Pages

  Friedland, Gerald ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV HCV; Substance abuse; TB

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; GAMMA INTERFERON; INTERFERON; ISONIAZID; METHADONE; NEVIRAPINE; PYRAZINAMIDE; RIBAVIRIN; RIFABUTIN; RIFAMPICIN;

ANEMIA; ANTIMICROBIAL THERAPY; BACTERIAL TRANSMISSION; COMORBIDITY; DEPRESSION; DRUG BLOOD LEVEL; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FATIGUE; GRANULOCYTOPENIA; HEALTH PROGRAM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SHORT COURSE THERAPY; SUBSTANCE ABUSE; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

HEPATITIS C; HIV INFECTIONS; HUMANS; SUBSTANCE-RELATED DISORDERS; TUBERCULOSIS;

EID: 78449281527     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f9c0b6     Document Type: Review

References (53)

1. Bruce R, Altice F, Friedland G. HIV Disease Among Substance Misusers: Treatment Issues. San Diego, CA: Elsevier Inc; 2007.
2. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
3. Centers for Disease Control and Prevention. Viral hepatitis: statistics and surveillance. Available at: http://www.cdc.gov/hepatitis/statistics.htm. Accessed January 2010.
4. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis- United States, 2007. MMWR Surveill Summ. 2009;58:1-27.
5. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-2441.
6. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46:1852-1858.
7. Zhang C, Yang R, Xia X, et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr. 2002;29:191-196.
8. Naoumov NV. Hepatitis C virus infection in Eastern Europe. J Hepatol. 1999;31(Suppl 1):84-87.
9. Hagan H, Campbell J, Thiede H, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710-719.
10. Strader DB. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis. 2005;41(Suppl 1):S7-S13.
11. Institute of Medicine. Hepatites and Liver Cancer: A National Strategy for Prevention and Control of Hepaptites B and C. Washington, DC. National Academies Press; 2010.
12. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.
13. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co infected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
14. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
15. Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr HIV/AIDS Rep. 2004;1:128-135.
16. Schiavini M, Angeli E, Mainini A, et al. Risk factors for fibrosis progression in HIV/HCV co infected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med. 2006;7:331-337.
17. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-co infected patients. J Viral Hepat. 2007;14:371-386.
18. Soriano V, Puoti M, Sulkowski M, et al. Care of patients co infected with HIVand hepatitis C virus: 2007 updated recommendations from the HCVHIV International Panel. AIDS. 2007;21:1073-1089.
19. Scott JD, Wald A, Kitahata M, et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS. 2009;23:925-929.
20. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33:126-133.
21. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009; 37:32-40.
22. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188-194.
23. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat. 2010;38:338-345.
24. Maru DS, Bruce RD, Basu S, et al. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47:952-961.
25. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211-215.
26. World Health Organization. Global Tuberculosis Control-Surveillance, Planning, Financing 2009. Geneva, Switzerland: WHO; 2009.
27. Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis. 2007;196(Suppl 1):S1-S3.
28. World Health Organization.Deaths by Cause, Sex and Mortality Stratum in WHO Regions, Estimates for 2002. World Health Report 2004-Changing History. Geneva, Switzerland: WHO; 2004.
29. World Health Organization.Global tuberculosis control-surveillance, planning, financing 2008. Geneva, Switzerland: WHO; 2008.
30. CDC. Reported HIV Status of Tuberculosis Patients-United States, 1993-2005. MMWR. 2007;56:1103-1106.
31. Oeltmann JE, Kammerer JS, Pevzner ES, et al. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med. 2009;169:189-197.
32. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
33. Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis. 2010;50(Suppl 3):S231-S237.
34. World Health Organization. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. Geneva, Switzlerland: WHO; 2009 (WHO/HTM/TB/2009.419).
35. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, Switzerland: WHO; 2008.
36. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80-86.
37. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-1580.
38. Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr Infect Dis Rep. 2007;9:252-261.
39. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr. 2009;50:37-43.
40. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:929-934. (Pubitemid 38944088)
41. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
42. Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41:563-572.
43. Bruce RD, McCance-Katz E, Kharasch ED, et al. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43(Suppl 4):S216-S223.
44. Bruce RD, Altice F, Friedland G. Pharmacokinetics drug interections between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2008;1: 115-127.
45. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; Injection Drug Users. NIH, DHHS, Washington, DC; 2009. Available at: AIDS info Web site. http://aidsinfo.nih.gov. Accessed May 10, 2010.
46. CDC. Centers for disease control and prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2008. Available at: www.cdc.gov/tb/publications/guidelines/TB-HIV-Drugs/default.htm. Accessed May 13, 2010.
47. McCance-Katz EF, Mandell TW. Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict. 2010;19:2-3.
48. CDC. Centers of Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000. Available at: www.cdc.gov/nchstp/tb/. 2000;49: 185-189.
49. Kreek MJ, Garfield JW, Gutjahr CL, et al. Rifampin-induced methadone withdrawal. N Engl J Med. 1976;294:1104-1106.
50. Friedland G, Khoo S, Jack C, et al. Administration of efavirenz (600 mg/ day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299-1302.
51. Raviglione MC.WHO stop TB strategy. Available at: http://www.stopTB.org. Accessed May 10, 2010.
52. World Health Organization. Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users: An Integrated Approach. Geneva, Switzerland: Department ST, editor; 2008.
53. Sylla L, Bruce RD, Kamarulzaman A, et al. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007;18:306-312.